MedTrace Logo

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

NCT02687490 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2021-03-01

No results posted yet for this study

Summary

Abraxane in patients with visceral metastases dominant metastatic breast cancer

Conditions

Interventions

DRUG

Abraxane

125 mg/m2, D1, D8, D15

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xichun Hu, MD, PhD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-24
Primary Completion
2020-12-01
Completion
2020-12-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687490 on ClinicalTrials.gov